Who are Imipenem and Cilastatin Sodium's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/imipenem-and-cilastatin-sodium.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Imipenem and Cilastatin Sodium — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Imipenem and Cilastatin Sodium (Imipenem and Cilastatin Sodium) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Beta-lactam antibiotic (carbapenem) with dehydropeptidase inhibitor. Area: Infectious Disease.

marketed Beta-lactam antibiotic (carbapenem) with dehydropeptidase inhibitor Penicillin-binding proteins (PBPs); bacterial cell wall peptidoglycan; renal dehydropeptidase I Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Imipenem and Cilastatin Sodium (Imipenem and Cilastatin Sodium) — Jiangsu HengRui Medicine Co., Ltd.. Imipenem inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, while cilastatin prevents imipenem degradation by inhibiting renal dehydropeptidase I.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Imipenem and Cilastatin Sodium TARGET	Imipenem and Cilastatin Sodium	Jiangsu HengRui Medicine Co., Ltd.	marketed	Beta-lactam antibiotic (carbapenem) with dehydropeptidase inhibitor	Penicillin-binding proteins (PBPs); bacterial cell wall peptidoglycan; renal dehydropeptidase I

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Beta-lactam antibiotic (carbapenem) with dehydropeptidase inhibitor class)

Jiangsu HengRui Medicine Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Imipenem and Cilastatin Sodium — Competitive Intelligence Brief. https://druglandscape.com/ci/imipenem-and-cilastatin-sodium. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab